Moxifloxacin was particularly effective in HR-negative (hormone receptor-negative) and HER2-positive (human epidermal growth factor receptor 2-positive) patients, potentially due to its ability to eradicate tumor-associated microbiota that contributed to tumor progression, chemoresistance, and angiogenesis [108]. The gene discussed is NR4A1; the disease is neoplasm.